Ignite Creation Date:
2024-05-05 @ 5:23 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00449202
Status:
UNKNOWN
Last Update Posted:
2007-03-20
First Post:
2007-03-16
Brief Title:
Phase 2a Obesity Study of Oral Doses of Oleoyl-Estrone MP-101
Sponsor:
Manhattan Pharmaceuticals
Organization:
Manhattan Pharmaceuticals
Study Overview
Official Title:
A Phase 2a Randomized Double-Blind Placebo Controlled Parallel Group Safety and Efficacy Study of Two 14 Day Cycles of Oral Doses of Oleoyl-Estrone MP-101 in Obese Adult Subjects
Status:
UNKNOWN
Status Verified Date:
2007-03
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
True
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety preliminary efficacy and pharmacokinetics of two 14-day cycles of escalating oral doses of MP 101 in 100 obese adult subjects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None